Results 51 to 60 of about 93,898 (384)

Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study)

European Respiratory Journal, 2021
Background The long-term efficacy and safety of mepolizumab for treatment of severe eosinophilic asthma are well established. Here, we examine the clinical impact of stopping mepolizumab after long-term use.
W. Moore, O. Kornmann, M. Humbert, C. Poirier, E. Bel, Norihiro Kaneko, Steven G. Smith, N. Martin, M. Gilson, R. Price, E. Bradford, M. Liu   +11 more
semanticscholar   +1 more source

Management of Severe Asthma in Eosinophilic Granulomatosis with Polyangiitis with Interleukin-5-Targeted Therapies: Current Status and Report of Two Cases

Applied Sciences, 2022
Eosinophilic granulomatosis with polyangiitis (EGPA) is a systemic disorder characterized by peripheral eosinophilia, severe eosinophilic asthma, sinusitis, transient pulmonary infiltrates, and features of medium/small-vessel vasculitis.
Ciro Romano, Domenico Cozzolino, Ausilia Sellitto, Luca Rinaldi   +3 more
doaj   +1 more source

Steroids in pediatric eosinophilic esophagitis [PDF]

, 2014
Swallowed fluticasone and oral viscous budesonide are effective first-line therapies for eosinophilic esophagitis in children. Side effects are minimal without evidence of Cushing syndrome, as seen in treatment with systemic corticosteroids.
Contreras, Emily M., Gupta, Sandeep K.
core   +1 more source

Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines ‐ recommendations on the use of biologicals in severe asthma

Allergy. European Journal of Allergy and Clinical Immunology, 2020
Five biologicals have been approved for severe eosinophilic asthma, a well‐recognized phenotype. Systematic reviews (SR) evaluated the efficacy and safety of benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab (alphabetical order) compared to
I. Agache, Jessica Beltran, C. Akdis, M. Akdiş, C. Canelo-Aybar, W. Canonica, T. Casale, T. Chivato, J. Corren, S. D. Del Giacco, T. Eiwegger, D. Firinu, J. Gern, E. Hamelmann, N. Hanania, M. Mäkelä, I. H. Martín, Parameswaran Nair, L. O’Mahony, N. Papadopoulos, A. Papi, Hae‐Sim Park, L. A. Pérez de Llano, M. Posso, Claudio Rocha, S. Quirce, J. Sastre, M. Shamji, Yang Song, Corinna Steiner, J. Schwarze, P. Alonso-Coello, Ó. Palomares, M. Jutel   +33 more
semanticscholar   +1 more source

Characterization and Factors Associated with Poor Asthma Control in Adults with Severe Eosinophilic Asthma

Journal of Personalized Medicine, 2023
A study was conducted in 98 adult patients diagnosed with severe eosinophilic asthma (73.5% women, mean age 47.2 years) and followed prospectively for 1 year.
Clara Padró-Casas, M. Basagaña, María Luisa Rivera-Ortún, I. García-Olivé, Carlos Pollan-Guisasola, A. Teniente‐Serra, E. Martínez-Cáceres, J. Navarro, J. Abad-Capa, A. Rosell, A. Roger, Carlos Martínez-Rivera   +11 more
semanticscholar   +1 more source

Benralizumab in Patients with Severe Eosinophilic Asthma: A Multicentre Real-Life Experience

Journal of Clinical Medicine, 2023
Background: Mepolizumab and benralizumab are monoclonal antibodies directed against anti-IL-5 and anti-IL5R, respectively, and their use reduces the exacerbation rate and maintains oral corticosteroid requirements in severe eosinophilic asthma.
G. Scioscia, Pasquale Tondo, S. Nolasco, C. Pelaia, G. E. Carpagnano, M. Caiaffa, G. Valenti, A. Maglio, F. Papia, M. Triggiani, N. Crimi, G. Pelaia, A. Vatrella, M. F. Foschino Barbaro, C. Crimi   +14 more
semanticscholar   +1 more source

Treating Acute Severe Eosinophilic Asthma with IL-5 Inhibitors in ICU

Case Reports in Pulmonology, 2022
Introduction. About 10% of the 300 million people worldwide who suffer from asthma have a severe disease that is uncontrolled despite treatment with inhaled corticosteroids and long-acting beta agonists.
Nicolas Barbarot, Emmanuelle Nourry, Nicolas Massart, François Legay, Matthieu Debarre, Pierre Fillatre, Eric Magalhaes, Arnaud Mari, Julien Wallois, Eric Briens, Stéphane Jouneau   +10 more
doaj   +1 more source

Long-Term Efficacy and Clinical Remission After Benralizumab Treatment in Patients with Severe Eosinophilic Asthma: A Retrospective Study

Journal of Asthma and Allergy, 2022
Background Few studies on the long-term efficacy of benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, have been conducted for patients with severe eosinophilic asthma (SEA), especially regarding the improvement of pulmonary function and
T. Numata, Jun Araya, Keitaro Okuda, H. Miyagawa, S. Minagawa, Takeo Ishikawa, Hiromichi Hara, K. Kuwano   +7 more
semanticscholar   +1 more source

Benralizumab improves symptoms of patients with severe, eosinophilic asthma with a diagnosis of nasal polyposis

Allergy. European Journal of Allergy and Clinical Immunology, 2021
Clinically meaningful improvement in the Sino‐Nasal Outcome Test‐22 (SNOT‐22) was observed in patients with severe, eosinophilic asthma, and nasal polyposis (NP) treated with benralizumab in the ANDHI trial.
G. Canonica, T. Harrison, P. Chanez, F. Menzella, R. Louis, B. Cosío, N. Lugogo, A. Mohan, A. Burden, E. Garcia Gil   +9 more
semanticscholar   +1 more source

Concentrations of Cysteinyl Leukotrienes in Various Biological Fluids of Children with Bronchial Asthma, Atopic Dermatitis and Food Protein Induced Enterocolitis [PDF]

, 2019
Clinical manifestation of food allergy is characterized by polymorphic cutaneous, respiratory and gastrointestinal syndromes. Leukotrienes occupy a key place in the pathogenesis of a wide range of inflammatory diseases, including bronchial asthma ...
Haiduchyk, H. (Halyna), Shadrin, O. (Oleg)   +1 more
core   +3 more sources